Corporate
Omeros Wins FDA Approval for YARTEMLEA, First-Ever Treatment for Often-Fatal Transplant Complication
Dec 24, 2025
You're signed outSign in or to get full access.
O
OMEROS (OMER)·Earnings Reports
Q3 2025
View earnings summary and analysis
Q2 2025
View earnings summary and analysis
Q1 2025
View earnings summary and analysis
Q4 2024
View earnings summary and analysis
Research analysts covering OMEROS.